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ABSTRACT
Chromogranin A (CgA) is gaining acceptance as a serum marker
of neuroendocrine tumors. Its specificity in differentiating between
neuroendocrine and nonneuroendocrine tumors, its sensitivity to de-
tect small tumors, and its clinical value, compared with other neu-
roendocrine markers, have not clearly been defined, however. The
objectives of this study were to evaluate the clinical usefulness of CgA
as neuroendocrine serum marker. Serum levels of CgA, neuron-spe-
cific enolase (NSE), and the a-subunit of glycoprotein hormones (a-
SU) were determined in 211 patients with neuroendocrine tumors and
180 control subjects with nonendocrine tumors. The concentrations of
CgA, NSE, and a-SU were elevated in 50%, 43%, and 24% of patients
with neuroendocrine tumors, respectively. Serum CgA was most fre-
quently increased in subjects with gastrinomas (100%), pheochromo-
cytomas (89%), carcinoid tumors (80%), nonfunctioning tumors of the
endocrine pancreas (69%), and medullary thyroid carcinomas (50%).
The highest levels were observed in subjects with carcinoid tumors.
NSE was most frequently elevated in patients with small cell lung
carcinoma (74%), and a-SU was most frequently elevated in patients
with carcinoid tumors (39%). Most subjects with elevated a-SU levels
also had elevated CgA concentrations. A significant positive relation-
ship was demonstrated between the tumor load and serum CgA levels
(P , 0.01, by x2 test). Elevated concentrations of CgA, NSE, and a-SU
were present in, respectively, 7%, 35%, and 15% of control subjects.
Markedly elevated serum levels of CgA, exceeding 300 mg/L, were
observed in only 2% of control patients (n 5 3) compared to 40% of
patients with neuroendocrine tumors (n 5 76). We conclude that CgA
is the best general neuroendocrine serum marker available. It has the
highest specificity for the detection of neuroendocrine tumors com-
pared to the other neuroendocrine markers, NSE and a-SU. Elevated
levels are strongly correlated with tumor volume; therefore, small
tumors may go undetected. Although its specificity cannot compete
with that of the specific hormonal secretion products of most neu-
roendocrine tumors, it can have useful clinical applications in subjects
with neuroendocrine tumors for whom either no marker is available
or the marker is inconvenient for routine clinical use. (J Clin Endo-
crinol Metab 82: 2622–2628, 1997)
CHROMOGRANIN A (CgA) is a protein that is presentin the secretory dense core granules of neuroendocrine
tissues (1). It is widely used as an immunohistochemical
marker of neuroendocrine tumors. It can also serve as a
serum marker, as it is cosecreted with the amines and pep-
tides that are present in the neurosecretory granules (2). It is
at present considered to be a very sensitive and specific
serum marker of neuroendocrine tumors. The concentrations
often remain increased in cases of less well differentiated
tumors of neuroendocrine origin that do not secrete known
hormones (3). The publications on CgA as a serum marker
of neuroendocrine neoplasia deal with rather small numbers
of patients and small numbers of control subjects with non-
neuroendocrine neoplasms (2, 4, 5). Most neuroendocrine
tumors included are far advanced, with a large tumor vol-
ume. Data on the specificity of CgA for the differentiation
between neuroendocrine and nonneuroendocrine tumors
and on its sensitivity for the detection of small neuroendo-
crine tumors are sparse or lacking. There are also no large
studies available in which CgA is compared with other neu-
roendocrine markers, such as neuron-specific enolase (NSE)
and the a-subunit of glycoprotein hormones (a-SU).
We investigated the roles of the serum concentrations of
CgA, NSE, and a-SU in a large study group of patients with
neuroendocrine tumors, including tumors with a small vol-
ume, and in a control group consisting of patients with sev-
eral nonendocrine tumors. The results suggest that the de-
termination of CgA is useful in selected clinical conditions
when either no known specific peptide markers are available




Serum samples were obtained from 211 subjects with the following
neuroendocrine neoplasms: carcinoid tumor (n 5 62), medullary thyroid
carcinoma (n 5 26), paraganglioma (n 5 25), pheochromocytoma (n 5
9), neuroblastoma (n 5 3), small cell lung carcinoma (n 5 23), insulinoma
(n 5 21), gastrinoma (n 5 9), nonfunctioning pancreatic islet cell tumor
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(n 5 13), Merkel cell tumor (n 5 4), clinically nonfunctioning pituitary
adenoma (n 5 10), and GH-secreting pituitary adenoma (n 5 6). All
diagnoses were made histologically, except in a few patients with small
tumors of the neuroendocrine pancreas. In these cases the following
diagnostic criteria were used: paradoxical rise in gastrin levels after
stimulation by iv injection of secretin in gastrinoma, and hypoglycemia
with inappropriate hypersecretion of insulin and C peptide during a
diagnostic fast in insulinoma. All plasma samples were obtained before
operation.
Serum samples were also obtained from 180 subjects with a variety
of “control” neoplasms of nonendocrine origin, both benign and ma-
lignant, including hematological and neurological tumors. This control
group consisted of patients with breast carcinoma (n 5 64), nonsmall cell
lung cancer (n 5 24), pancreatic adenocarcinoma (n 5 21), adenocarci-
noma of unknown origin (n 5 12), non-Hodgkin lymphoma (n 5 25),
Hodgkin lymphoma (n 5 13), multiple myeloma (n 5 7), meningioma
(n 5 10), and astrocytoma (n 5 4). All of these diagnoses were confirmed
by histological examination.
Immunoassays
CgA was measured in serum samples, stored at 220 C, by a poly-
clonal RIA, using human CgA isolated from pheochromocytomas as
tracer and standard, as previously described (6). The within-assay co-
efficients of variation were 6.5% and 8.6% for mean concentrations of 95
and 1160 ng/mL (n 5 18), respectively. The between-assay coefficients
of variation were 6.9% and 6.3% for mean concentrations of 90 and 698
ng/mL (n 5 38), respectively. The detection sensitivity was 1.6 mg/L.
The CgA immunoreactivity remained stable whether the serum samples
were immediately frozen or kept at 4 C or at room temperature for 24 h,
or whether blood was centrifuged immediately to obtain serum or after
24-h storage at room temperature. The reference value in 568 normal
subjects of both sexes, aged 6–50 yr, is 90 6 24 mg/L (range, 35–176); in
33 normal men older than 50 yr, it is 106 6 22 mg/L (range, 70–159); in
249 normal postmenopausal women older than 50 yr, it is 110.1 6 35.5
mg/L (range, 54–220). In men and premenopausal women, 175 mg/L
was chosen as the upper cut-off value, and in postmenopausal women,
220 mg/L was used, to avoid overlapping values with normal subjects.
This corresponds to slightly more than 3 sd above the mean.
NSE was measured by RIA. The upper cut-off value is 12.5 mg/L.
a-Subunit was measured by RIA using antibodies purchased from
UCB (Brussels, Belgium). The upper cut-off values are 1.1 mg/L in men,
2.3 mg/L in premenopausal women, and 4.0 mg/L in postmenopausal
women.
Determination of tumor mass
The number of neuroendocrine tumor localizations was counted us-
ing computed tomography scan images and [111In-DTPA-d-
Phe1]octreotide scanning (7). The tumor load was considered limited
when one or two localizations were found; it was considered extensive
when more than three localizations were demonstrated.
Statistical analysis
Results are reported as the mean 6 sd. To compare the different
markers, x2 tests and Spearman rank correlations were used. To study
the effect of tumor load on circulating concentrations of the markers, x2
tests were used.
Results
Serum concentrations of the markers CgA, a-SU, and NSE
were determined in 211 patients with neuroendocrine tu-
mors and compared to levels in a control group, consisting
of 180 patients with nonendocrine neoplasms. The study and
control groups showed comparable age distributions (53 6
14 and 54 6 13 yr, respectively). The sex distribution showed
a higher male/female ratio for the study group (1.67 vs. 0.68),
which can be ascribed to the high number of patients with
breast carcinoma in the control group.
Because renal failure can increase circulating CgA con-
centrations (4), we evaluated whether this could cause falsely
elevated levels. In the control group a significant relationship
was demonstrated between a serum creatinine level higher
than 133 mmol/L and increased levels of CgA (P , 0.001, by
x2 test). A creatinine concentration above 133 mmol/L was
found in seven patients in the control group. Elevated serum
concentrations of CgA (maximum, 371 mg/L) were present
in six of these patients. A creatinine level above 133 mmol/L
was also present in three subjects in the study group (all with
carcinoid tumor). One of these patients had normal and one
had slightly increased CgA concentrations (268 mg/L). The
third patient, with an extensively metastasized carcinoid tu-
mor, had a creatinine level of 220 mmol/L and very high
levels of CgA (188, 160 mg/L). Although these extreme ele-
vations probably cannot be attributed to the diminished renal
function (4), these three study patients and seven control
subjects with creatinine levels above 133 mmol/L were elim-
inated for further analysis of the data. Slightly elevated CgA
concentrations can also occur in cases of severe liver dys-
function (4). This was not encountered in any of our study
or control patients.
The results are summarized in Tables 1 and 2 and Fig. 1.
The serum concentrations of CgA were elevated in 103 of 208
patients with neuroendocrine tumors. They were more fre-
quently increased (in 50% of the subjects) than the concen-
trations of NSE and a-SU (in 43% and 24% of the subjects,
respectively). The highest elevations of CgA were observed
in subjects with carcinoid tumors (up to a maximum of 52,340
mg/L). Very high levels (.1,000 mg/L) were also seen in
subjects with nonfunctioning pancreatic islet cell tumor,
medullary thyroid carcinoma, pheochromocytoma, paragan-
glioma, small cell lung carcinoma, gastrinoma, and Merkel
cell tumor. The levels were most frequently elevated in sub-
jects with gastrinoma (100%), pheochromocytoma (89%), and
carcinoid tumor (80%). In subjects with pituitary adenoma
(13%), insulinoma (10%), and paraganglioma (8%), elevated
CgA levels were only rarely present (Tables 1 and 2 and Fig.
1).
The highest levels of NSE were recorded in patients with
small cell lung carcinoma and Merkel cell tumor (up to a
maximum of 558 mg/L). NSE was more frequently elevated
than CgA in subjects with small cell lung carcinoma (in 74%
and 39%, respectively), Merkel cell tumor (in 50% and 25%,
respectively), insulinoma (in 38% and 10%, respectively),
paraganglioma (in 36% and 8%, respectively), and neuro-
blastoma (in 67% and 33%, respectively).
The levels of a-SU were most frequently elevated in pa-
tients with carcinoid tumors (39%). Very high levels (up to
a maximum of 353 mg/L) were found in these patients. a-SU
concentrations higher than 10 mg/L were found in 7 of 59
subjects with carcinoid tumors (12%), whereas they were
never encountered in subjects with other neuroendocrine
neoplasms.
Elevated levels of CgA, a-SU, and NSE were present in
respectively 9 (69%), 4 (31%), and 3 (23%) of 13 patients with
nonfunctioning pancreatic islet cell tumors (Table 3). In 7
(54%) of these 13 patients, CgA levels were markedly ele-
vated (.300 mg/L).
Elevated levels of CgA, a-SU, and NSE were present in,
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respectively, 7%, 15%, and 35% of control subjects with non-
endocrine neoplasms.
When these control subjects were used as reference pop-
ulation, the sensitivities of CgA, NSE, and a-SU for the di-
agnosis of peripheral neuroendocrine tumors (pituitary ad-
enomas excluded) were, respectively, 53%, 46%, and 26%,
with specificities of 93%, 65%, and 85%. We applied, how-
ever, a rather high upper cut-off value for CgA, correspond-
ing to slightly more than 3 sd above the mean, to avoid
overlapping values with normal subjects. Usually 2 sd above
the mean is used as the upper cut-off level, increasing the risk
of overlap. When we reanalyzed our data using 2 sd as the
upper cut-off level, the sensitivity hardly improved to 58%
with a specificity of 90%. When using 300 mg/L as the upper
TABLE 1. Serum levels of CgA, NSE, and a-SU in patients with neuroendocrine tumors and in controls with nonendocrine tumors
Type of tumor No. ofsubjects
CgA (mg/L) NSE (mg/L) a-SU (mg/L)
Median Range Median Range Median Range
Neuroendocrine tumors (n 5 208)
Carcinoid tumor 59 688 33–52,340 12 6–156 1.5 0.6–353.0
Medullary thyroid carcinoma 26 184 80–13,900 11 4–146 1.1 0.6–3.7
Paraganglioma 25 106 50–11,590 10 6–35 0.9 0.6–2.0
Pheochromocytoma 9 275 110–4,674 11 1–19 0.9 0.6–1.8
Neuroblastoma 3 133 117–238 36 12–100 0.6 0.3–3.0
Small cell lung carcinoma 23 149 45–2,948 27 6–511 1.2 0.5–2.5
Insulinoma 21 105 63–236 12 5–19 1.1 0.5–3.4
Gastrinoma 9 772 289–1,933 13 8–23 1.6 0.5–4.7
NF pancreatic islet cell tumor 13 306 85–14,750 10 5–91 1.1 0.7–2.1
Merkel cell tumor 4 109 84–1,056 23 7–558 1.0 0.6–2.5
Clinically NF pituitary adenoma 10 131 85–240 10 8–12 0.9 0.6–3.6
GH-secreting pituitary adenoma 6 71 53–115 8 6–10 0.9 0.5–1.7
Nonendocrine tumors (n 5 173)
Breast carcinoma 62 96 55–8,307 11 4–26 1.5 0.4–13.0
Nonsmall cell lung cancer 23 95 47–219 11 5–41 1.1 0.6–6.7
Pancreatic adenocarcinoma 20 116 51–395 11 6–24 1.1 0.5–2.9
Adenocarcinoma uo 12 119 68–154 12 7–44 1.3 0.7–2.7
Non-Hodgkin lymphoma 24 99 67–185 10 5–22 1.1 0.5–2.3
Hodgkin lymphoma 13 75 22–161 10 6–52 1.0 0.7–1.4
Multiple myeloma 5 162 98–215 13 9–15 1.1 0.8–1.7
Meningioma 10 89 57–134 11 6–32 1.0 0.4–2.6
Astrocytoma 4 86 66–121 6 5–52 0.8 0.6–0.8
NF, Nonfunctioning; uo, unknown origin.
TABLE 2. Presence of elevated serum levels of CgA, NSE, and a-SU in patients with neuroendocrine tumors and controls with
nonendocrine tumors
Type of tumor No. ofsubjects
1 CgA 1 NSE 1 a-SU
n % n % n %
Neuroendocrine tumors
Carcinoid tumor 59 47 80 28 47 23 39
Medullary thyroid carcinoma 26 13 50 11 42 5 19
Paraganglioma 25 2 8 9 36 3 12
Pheochromocytoma 9 8 89 4 44 1 11
Neuroblastoma 3 1 33 2 67 1 33
Small cell lung carcinoma 23 9 39 17 74 8 35
Insulinoma 21 2 10 8 38 0 0
Gastrinoma 9 9 100 4 44 3 33
NF pancreatic islet cell tumor 13 9 69 4 31 3 23
Merkel cell tumor 4 1 25 2 50 0 0
Clinically NF pituitary adenoma 10 2 20 0 0 2 20
GH-secreting pituitary adenoma 6 0 0 0 0 0 0
Total 208 103 50 89 43 49 24
Nonendocrine tumors
Breast carcinoma 62 5 8 23 37 6 10
Nonsmall cell lung carcinoma 23 1 4 9 39 4 17
Pancreatic adenocarcinoma 20 3 15 7 35 2 10
Adenocarcinoma uo 12 0 0 6 50 2 17
Non-Hodgkin lymphoma 24 1 4 5 21 5 21
Hodgkin lymphoma 13 0 0 3 23 4 31
Multiple myeloma 5 2 40 3 60 2 40
Meningioma 10 0 0 4 40 1 10
Astrocytoma 4 0 0 1 25 0 0
Total 173 12 7 61 35 26 15
n, Number of subjects with elevated levels.
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cut-off concentration for CgA, elevated levels were found in
only 3 of 173 patients (2%) with nonneuroendocrine control
tumors compared to 76 of 192 patients (40%) with peripheral
neuroendocrine tumors (sensitivity, 40%; specificity, 98%).
Thus, finding an excessively elevated level of CgA firmly
suggests the presence of a neuroendocrine tumor.
Relationships among the general neuroendocrine markers
CgA, NSE, and a-SU
In subjects with peripheral neuroendocrine tumors (pitu-
itary adenomas excluded), a statistically significant relation-
ship was demonstrated between the presence and absence of
elevated serum levels of CgA and a-SU (P , 0.001, by x2 test),
but not between CgA and NSE or between a-SU and NSE
(Table 4). A weak, but significant, relationship was present
between the presence and absence of elevated serum con-
centrations of CgA and a-SU (P 5 0.05, by x2 test) in subjects
with carcinoid tumors, who frequently had elevated a-SU
levels. In patients with small cell lung carcinoma, who fre-
quently had elevated NSE levels, no significant relationship
could be shown between CgA and NSE concentrations.
Relationship with other neuroendocrine markers
Measurements of 24-h urinary 5-hydroxyindole acetic acid
(5-HIAA) excretions were available in 46 of 59 patients with
carcinoid tumors. Increased levels (.40 mmol/24 h) were
present in 31 patients (67%). Elevated serum concentrations
of CgA were demonstrated in 30 of these 31 subjects (97%;
P , 0.01, by x2 test). A significant correlation was also present
between the absolute values of serum CgA and 24-h urinary
5-HIAA excretion (Spearman rank correlation test; r 5 0.65;
P , 0.01). No significant relationships were demonstrated
between a-SU and NSE concentrations, on the one hand, and
urinary 5-HIAA excretions, on the other hand (P . 0.05, by
x2 tests).
Determinations of serum calcitonin and carcinoembryonic
antigen (CEA) concentrations were available in, respectively,
20 and 21 of 26 subjects with medullary thyroid carcinoma.
Calcitonin was elevated (.0.14 mg/L) in 18 of 20 patients
(90%), and CEA (.10 mg/L) was elevated in 18 of 21 patients
(86%). Elevated CEA levels were present in the 2 patients
with normal calcitonin levels. In 1 of these 2 subjects, slightly
elevated concentrations of CgA (192 mg/L) and a-SU (1.5
mg/L) were found. CgA, a-SU, and NSE levels were not
increased in the 3 patients with normal CEA levels. Signif-
icant correlations were demonstrated between serum CgA,
on the one hand, and calcitonin (by Spearman rank corre-
lation test: r 5 0.79; P , 0.01) and CEA (r 5 0.84; P , 0.01),
FIG. 1. Serum concentrations of CgA in
patients with neuroendocrine tumors
and in controls with nonendocrine tu-
mors. Individual levels are presented as
dots; median levels as lines. The dashed
line represents the upper cut-off level of
220 mg/L. The results are plotted loga-
rithmically to accommodate extreme
values. MTC, Medullary thyroid carci-
noma; Pheo, Pheochromocytoma;
SCLC, Small cell lung carcinoma; GH,
GH-producing; NF, Nonfunctioning.
TABLE 3. Serum levels of CgA, NSE, a-SU in patients with
nonfunctioning tumors of the endocrine pancreas
Patient no. Sex Age (yr) CgA (mg/L) NSE (mg/L) a-SU (mg/L)
1 M 56 969a 11.4 1.9a
2 V 67 306a 4.6 1.7
3 M 23 999a 5.6 1.1
4 V 55 14,750a 10.3 2.1
5 V 51 94 12.6a 2.0
6 M 72 641a 6.8 1.3a
7 M 70 207a 15.5a 1.0
8 V 46 99 11.0 1.0
9 M 51 910a 90.8a 1.1
10 M 64 211a 8.1 1.0
11 M 59 85 5.3 0.7
12 M 51 126 15.6a 1.2a
13 M 63 567a 8.0 0.7
a Elevated levels.
Upper cut-off values: CgA (micrograms per L), 175 in men and
premenopausal women, 220 in postmenopausal women; NSE (micro-
grams per L), 12.5; a-SU (micrograms per L), 1.1 in men, 2.3 in
premenopausal women, and 4.0 in postmenopausal women.
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on the other hand, as well as between NSE, on the one hand,
and calcitonin (r 5 0.71; P , 0.01) and CEA (r 5 0.82; P ,
0.01), on the other hand. a-SU showed a correlation with
calcitonin (r 5 0.63; P , 0.01), but no significant correlation
with CEA (r 5 0.33; P . 0.05).
Determinations of 24-h urinary excretions of vanilman-
delic acid (VMA) were only available in five of nine patients
with pheochromocytoma. The highest levels of CgA were
found in the patients with the highest urinary VMA excre-
tion, although the small number of cases did not permit
statistical evaluation.
Relationship with tumor load
Using computed tomography scan images and octreotide
scintigrams, information on tumor volume could be obtained
in subjects with the following neuroendocrine neoplasms: 60
carcinoid tumors, 26 medullary thyroid carcinomas, 25 para-
gangliomas, 11 small cell lung carcinomas, 9 gastrinomas,
and 12 nonfunctioning pancreatic islet cell tumors. Tumor
load was considered to be limited when 1 or 2 localizations
were found and was considered extensive when more than
3 localizations were demonstrated. A highly significant pos-
itive relationship was demonstrated between the tumor load
and serum CgA levels (P , 0.01, by x2 test). Such a relation-
ship could not be shown for a-SU or NSE. In the individual
neuroendocrine neoplasms, the relationship between tumor
load and CgA levels was only significant in subjects with
carcinoid tumors. Because they represent the largest sub-
group, statistical significance is more easily reached. Gastri-
nomas form an exception to the rule that small neuroendo-
crine tumors have low CgA levels; elevated CgA levels were
detected in all patients with gastrinomas, although they all
presented with limited neoplastic disease.
Discussion
We evaluated the clinical usefulness of CgA, NSE, and
a-SU as serum markers of neuroendocrine neoplasia in gen-
eral. Serum concentrations were measured in a large group
of patients with several neuroendocrine tumors and com-
pared with those in a large control group with a variety of
nonendocrine tumors.
The highest concentrations of CgA, with values up to 250
times the upper limit of normal, were observed in subjects
with carcinoid tumors, medullary thyroid carcinomas, pheo-
chromocytomas, and some tumors of the endocrine pan-
creas. This confirms the results of previous smaller studies (2,
4, 5). Elevated levels were also frequently encountered in
subjects with peripheral (nonpituitary) neuroendocrine tu-
mors without detectable hormonal secretion. These so-called
chromograninomas were first described by Sobol and co-
workers (3). Serum concentrations of CgA are only rarely
increased, however, in cases of clinically nonfunctioning pi-
tuitary adenomas. This is probably due to the small volume
of these adenomas (6).
We demonstrated a significant positive relation between
the serum levels of CgA and the tumor mass of the neu-
roendocrine neoplasms. This confirms our earlier findings in
Cushing’s syndrome caused by ectopic ACTH production by
extrapituitary neuroendocrine tumors (8) and the findings by
O’Connor and Deftos (2) and Hsiao and co-workers (9) in
pheochromocytomas. The serum concentrations of CgA are
only rarely slightly elevated in subjects with small neuroen-
docrine tumors, such as insulinomas, paragangliomas, or
pituitary adenomas (6, 8, 10). These tumors are usually de-
tected at an early stage of oncological evolution, because they
rapidly induce symptoms due to active hormonal secretion
or compression of important surrounding tissues. The pres-
ence of CgA or its messenger ribonucleic acid can nearly
always be demonstrated in the cells of these tumors by im-
munohistochemistry or in situ hybridization (6, 11, 12). Nev-
ertheless, it must be assumed that the small amount of CgA
released by these neoplasms usually fails to elevate the se-
rum concentration above the physiological background
level. Increased CgA concentrations were detected, however,
in all of our patients with gastrinoma, although they all had
a very limited tumor burden. It is well known that chronic
elevation of gastrin levels provokes hyperplasia of the neu-
roendocrine cells of the stomach (13). As these cells are able
to secrete CgA, they might be responsible for the elevated
CgA concentrations. Stabile and co-workers demonstrated
that the CgA concentrations can be normalized by gastrec-
tomy alone, without resection of the gastrin-producing tu-
mor (and thus without correction of the elevated gastrin
levels) (14).
In our hands, CgA had a smaller sensitivity for the de-
tection of neuroendocrine neoplasms than reported in pre-
vious studies (2, 4, 5). However, the technical characteristics
of our RIA for CgA are very similar to those of the other
assays used in frequently cited publications (4, 15). A small
neuroendocrine tumor mass was present in a rather large
percentage of our patients, in contrast to the hitherto pub-
lished series, in which almost all tumors were extensively
metastasized (2, 4, 5). This can probably be explained by the
fact that patients tend to be transferred earlier in their on-
cological evolution, after the development of [111In-DTPA-
d-Phe1]octreotide scanning for the visualization of neuroen-
docrine tumors in our hospital. Many patients with
biochemical proof of a neuroendocrine tumor were trans-












subjectsNormal Elevated Normal Elevated Normal Elevated
a-SU NSE a-SU
Normal 93 66 159 Normal 64 56 120 Normal 92 67 159
Elevated 12 38 50 Elevated 41 48 89 Elevated 28 22 50
No. of subjects 105 104 209 105 104 209 120 89 209
NS, P . 0.05.
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ferred for somatostatin receptor scintigraphy after conven-
tional radiography failed to elucidate the location of the
tumor. The inclusion of a number of patients with these
smaller tumors decreased the overall sensitivity of serum
CgA in our series.
The specificity of elevated levels of CgA in the diagnosis
of neuroendocrine tumors was also lower in our study than
in previous ones (2, 4, 5). O’Connor and co-workers (2, 4) and
Erikkson and co-workers (5) reported specificities of 100%.
By contrast, we used a much larger control group, consisting
of patients with a greater variety of nonendocrine tumors.
After excluding patients with decreased renal function, el-
evated serum concentrations of CgA were demonstrated in
12 of 173 nonendocrine neoplasms (7%). The serum levels in
these control patients were usually only slightly elevated.
They exceeded 300 mg/L in only 3 of 173 patients (2%) com-
pared to 76 of 208 patients (37%) with neuroendocrine tu-
mors. Thus, finding an excessively elevated level of CgA
firmly suggests the presence of a neuroendocrine tumor.
It is well established that many nonendocrine tissues con-
tain neuroendocrine cells, belonging to the amino-precursor-
uptake-decarboxylation system. A substantial body of data
has accumulated in the literature during recent years, re-
vealing that these cells are also present in most tumors of
nonendocrine origin (16–20). They are either diffusely scat-
tered throughout the tumor or multifocally located in small
nests. In malignant tumors these neuroendocrine cells even
participate in the neoplastic growth, as they show nuclear
abberations and are present in locally invasive or metastatic
tumor tissue. The number of tumors harboring these neu-
roendocrine cells or the percentage of neuroendocrine cells
in a tumor depend on the tumor type, the number of neu-
roendocrine markers used, and the detection technique (his-
tochemistry for argyrophilia, immunohistochemistry, or de-
tection of messenger ribonucleic acid of neuroendocrine
markers). These cells probably secrete CgA, as it is present
in their dense core secretory granules. There are only scarce
data available in the literature concerning serum levels of
CgA in subjects with nonendocrine tumors. Elevated levels
were reported in patients with carcinomas of the prostate
gland (21, 22) and in cases of nonsmall cell lung cancer (23).
Whether proliferation of neuroendocrine cells also occurs in
hematological neoplasms is not known. One study reported
the presence of scarcely distributed CgA-positive cells in the
normal spleen, lymph nodes, and thymus (24).
As a general neuroendocrine marker, CgA cannot differ-
entiate between different subtypes of neuroendocrine neo-
plasms. Most tumors of neuroendocrine origin release typ-
ical secretion products that can be used as specific serum
markers. These markers usually provide a higher sensitivity
and specificity than CgA, as illustrated by our data compar-
ing calcitonin and CEA with CgA in subjects with medullary
thyroid carcinoma. In these situations the usefulness of CgA
is limited, because it does not provide additional informa-
tion. By contrast, CgA can have interesting clinical applica-
tions in so-called nonfunctioning neuroendocrine tumors
that are either not able to secrete hormonal products or
release products that cannot be detected by current tech-
niques. It can also be useful in neuroendocrine tumors in
which other diagnostic procedures have their limitations (e.g.
fluctuating levels of serum catecholamines in pheochromo-
cytoma) or are inconvenient (e.g. 24-h urine collections for
5-HIAA determination in carcinoid tumors). Our data illus-
trate the value of CgA in these conditions: increased levels
were found in 69% of nonpituitary, hormone-negative neu-
roendocrine tumors, 89% of pheochromocytomas, and 80%
of carcinoid tumors. Very high concentrations were fre-
quently encountered in these patients.
NSE is the neuron-specific isomer of the glycolytic enzyme
2-phospho-d-glycerate hydrolase or enolase (25). It is a
widely used immunohistochemical and serum marker for
neuroendocrine tissues and is especially known as a marker
for small cell lung carcinoma (26). Our data confirm the
frequent elevation of its serum concentrations in patients
with several neuroendocrine tumors (27–29). The highest
levels were encountered in small cell lung carcinoma and in
the rare cases of Merkel cell tumors. Serum concentrations of
NSE are more often elevated than those of CgA in subjects
with these tumors and in those with insulinomas, paragan-
gliomas, and neuroblastomas. The specificity of serum NSE
for the diagnosis of neuroendocrine tumors is, however,
much lower than that of serum CgA. Increased NSE levels
were demonstrated in 61 of 173 subjects with nonneuroen-
docrine neoplasms (35%) compared to 89 of 192 with pe-
ripheral (nonpituitary) neuroendocrine tumors (46%). Un-
like CgA, the specificity of NSE can hardly be improved by
increasing the upper cut-off value. Therefore, NSE cannot be
considered a good diagnostic marker for neuroendocrine
tumors, but can be very useful as a follow-up marker, es-
pecially for small cell lung carcinoma and Merkel cell tumors.
The a-SU of the glycoprotein hormones is a well known
marker of pituitary adenomas of gonadotroph origin (6).
Recent studies suggest that determination of the serum con-
centrations of a-SU might also be of value in patients with
peripheral neuroendocrine neoplasms (30–32). Our data con-
firm the presence of elevated serum levels in several subjects
with these neoplasms. Again, as with CgA and NSE, the
marker lacks specificity. Serum levels were elevated in 26 of
173 subjects with nonneuroendocrine neoplasms (15%) com-
pared to 47 of 192 with peripheral neuroendocrine tumors
(24%). Increasing the cut-off level again failed to improve the
specificity. Very high levels were frequently detected in pa-
tients with carcinoid tumors; 7 of 59 subjects with carcinoid
tumors (12%) had levels higher than 10 mg/L. Such high
levels were only encountered once in the control group, in a
patient with breast carcinoma. Thus, the finding of very high
serum concentrations of a-SU suggests the presence of a
carcinoid tumor when tumors of germ cell or trophoblastic
origin are excluded. The clinical usefulness of a-SU as a
marker for neuroendocrine tumors is limited, however, be-
cause most subjects with elevated levels also have elevated
CgA concentrations.
In conclusion, CgA is the best general neuroendocrine
serum marker available. It had the highest specificity for the
detection of neuroendocrine tumors of the three tested mark-
ers. Unfortunately, it is not a very sensitive marker; its serum
concentrations seem to rise relatively late in the evolution of
the tumor. Although its specificity cannot compete with that
of the specific hormonal secretion products of most neu-
roendocrine tumors, it can have useful clinical applications
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in subjects with neuroendocrine tumors for which either no
marker is available (so-called nonfunctioning neuroendo-
crine tumors) or the marker is inconvenient for daily clinical
use (e.g. 24-h urinary 5-HIAA excretions and plasma
catecholamines).
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